Carbetocin is a cyclic octapeptide analogue of oxytocin in which the disulfide bridge of the parent molecule is replaced by a carbon–carbon bond (a carbetocin-specific 1-butanoic acid modification at the N-terminus), converting the structure from a cyclic nonapeptide to a more metabolically stable, lipophilic compound. This structural change confers a longer plasma half-life , approximately four to ten times that of oxytocin , and a prolonged duration of uterotonic activity following a single intramuscular or intravenous dose.
In Australia, carbetocin is a prescription-only medicine listed in Schedule 4 of the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons). It is registered with the Therapeutic Goods Administration (TGA) for use in clinical obstetric settings; its approved indication is the prevention of uterine atony and excessive bleeding following delivery of the infant by caesarean section under epidural or spinal anaesthesia. It is not approved for general performance-enhancement, anti-ageing, or any other non-obstetric purpose, and no such representations are permitted under Australian law.
Pharmacodynamically, carbetocin binds to oxytocin receptors (OTRs) , G-protein-coupled receptors coupled primarily to Gq/11; expressed on uterine smooth muscle (myometrium). Receptor activation initiates phospholipase C signalling, elevating intracellular calcium and promoting myometrial contraction. Compared with exogenous oxytocin infusion, a single bolus dose of carbetocin produces tonic uterine contraction that persists for one to two hours, which is the pharmacological basis for its clinical utility in reducing the need for additional uterotonics. Receptor binding also occurs in the central nervous system, though the significance of central OTR engagement following a single perioperative dose is not fully characterised in the published literature.
Any supply of carbetocin outside a TGA-approved and lawfully dispensed context, including compounded or imported preparations marketed for unapproved indications, is not legally permitted in Australia. The TGA actively monitors and enforces compliance with the Therapeutic Goods Act 1989 regarding unapproved peptide products.
Sources: